The state of complement in COVID-19

Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Afzali, Behdad, Noris, Marina, Lambrecht, Bart N., Kemper, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Progress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672651/
https://www.ncbi.nlm.nih.gov/pubmed/34912108
http://dx.doi.org/10.1038/s41577-021-00665-1
Descripción
Sumario:Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.

Ejemplares similares